Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-dose vs single-dose anti-CD25 monoclonal antibody (with methotrexate) for aGVHD prevention in haploidentical HSCT
ChiCTR2200060184Phase 3Recruiting
- Sponsor
- Union Hospital
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of basiliximab in Acute Leukaemia, myelodysplastic syndrome (MDS), Acute Graft-Versus-Host Disease (aGvHD) and 1 more (2 arms), sponsored by Union Hospital. Primary endpoint: Incidence of acute graft-versus-host disease (aGVHD). Started May 2022; status: recruiting.
02
Drugs
basiliximab
03
Conditions
Acute Leukaemiamyelodysplastic syndrome (MDS)Acute Graft-Versus-Host Disease (aGvHD)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2200060184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060184.